Evista is a medication used to treat and prevent osteoporosis in women. The active substance in Evista is raloxifene, which belongs to the group of selective estrogen receptor modulators (SERMs). Raloxifene works by binding to the estrogen receptors in the bones and other tissues, thus mimicking the effects of estrogen without some of its negative side effects.
Evista comes in the form of 28 pills, each containing 60 mg of raloxifene. The medication is intended to be taken once a day, preferably at the same time each day, with or without food. It is important to follow the dosing instructions provided by your doctor to ensure the maximum efficacy and safety of the medication.
Evista is manufactured by Daiichi Sankyo, a multinational pharmaceutical company based in Tokyo, Japan. The company has a history of over a century in developing and producing innovative medical treatments for various health conditions.
In addition to treating osteoporosis, Evista has been shown to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in women at high risk for developing breast cancer. The medication may also offer other health benefits, such as improving lipid profiles and reducing the risk of cardiovascular events.
However, like any medication, Evista may cause side effects, including hot flashes, joint pain, leg cramps, and peripheral edema. It may also increase the risk of blood clots, stroke, and endometrial cancer. Therefore, it is important to discuss the risks and benefits of taking Evista with your doctor and to report any side effects promptly.